Literature DB >> 34311111

Patient-Reported Outcome Measures Modestly Enhance Prediction of Readmission in Patients with Cirrhosis.

Eric S Orman1, Marwan S Ghabril2, Archita P Desai2, Lauren Nephew2, Kavish R Patidar2, Sujuan Gao3, Chenjia Xu3, Naga Chalasani2.   

Abstract

BACKGROUND & AIMS: Patients with cirrhosis have high rates of hospital readmission, but prediction models are suboptimal and have not included important patient-reported outcome measures (PROMs). In a large prospective cohort, we examined the impact of PROMs on prediction of 30-day readmissions.
METHODS: We performed a prospective cohort study of adults with cirrhosis admitted to a tertiary center between June 2014 and March 2020. We collected clinical information, socioeconomic status, and PROMs addressing functional status and quality of life. We used hierarchical competing risk time-to-event analysis to examine the impact of PROMs on readmission prediction.
RESULTS: A total of 654 patients were discharged alive, and 247 (38%) were readmitted within 30 days. Readmission was independently associated with cerebrovascular disease, ascites, prior hospital admission, admission via the emergency department, lower albumin, higher Model for End-Stage Liver Disease, discharge with public transportation, and impaired basic activities of daily living and quality-of-life activity domain. Reduced readmission was associated with cancer, admission for infection, children at home, and impaired emotional function. Compared with a model including only clinical variables, addition of functional status and quality-of-life variables improved the area under the receiver-operating characteristic curve from 0.72 to 0.73 and 0.75, with net reclassification indices of 0.22 and 0.18, respectively. Socioeconomic variables did not significantly improve prediction compared with clinical variables alone. Compared with a model using electronically available variables only, no models improved prediction when examined with integrated discrimination improvement.
CONCLUSIONS: PROMs may marginally add to the prediction of 30-day readmissions for patients with cirrhosis. Poor social support and disability are associated with readmissions and may be high-yield targets for future interventions.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Health services; Hepatology; Hospitalization

Mesh:

Year:  2021        PMID: 34311111      PMCID: PMC8784569          DOI: 10.1016/j.cgh.2021.07.032

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   13.576


  42 in total

1.  Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record.

Authors:  Kathleen E Corey; Uri Kartoun; Hui Zheng; Stanley Y Shaw
Journal:  Dig Dis Sci       Date:  2015-11-04       Impact factor: 3.199

Review 2.  Impact of social factors on risk of readmission or mortality in pneumonia and heart failure: systematic review.

Authors:  Linda Calvillo-King; Danielle Arnold; Kathryn J Eubank; Matthew Lo; Pete Yunyongying; Heather Stieglitz; Ethan A Halm
Journal:  J Gen Intern Med       Date:  2012-10-06       Impact factor: 5.128

3.  Variation among United States hospitals in inpatient mortality for cirrhosis.

Authors:  Jessica L Mellinger; Caroline R Richardson; Amit K Mathur; Michael L Volk
Journal:  Clin Gastroenterol Hepatol       Date:  2014-09-28       Impact factor: 11.382

4.  Predicting 30-Day Hospital Readmission Risk in a National Cohort of Patients with Cirrhosis.

Authors:  Jejo D Koola; Sam B Ho; Aize Cao; Guanhua Chen; Amy M Perkins; Sharon E Davis; Michael E Matheny
Journal:  Dig Dis Sci       Date:  2019-09-17       Impact factor: 3.199

5.  The Functional Status Questionnaire: reliability and validity when used in primary care.

Authors:  A M Jette; A R Davies; P D Cleary; D R Calkins; L V Rubenstein; A Fink; J Kosecoff; R T Young; R H Brook; T L Delbanco
Journal:  J Gen Intern Med       Date:  1986 May-Jun       Impact factor: 5.128

6.  HEPACONTROL. A program that reduces early readmissions, mortality at 60 days, and healthcare costs in decompensated cirrhosis.

Authors:  Betty P Morales; Ramon Planas; Ramon Bartoli; Rosa M Morillas; Margarita Sala; Irma Casas; Carolina Armengol; Helena Masnou
Journal:  Dig Liver Dis       Date:  2017-08-13       Impact factor: 4.088

7.  Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis.

Authors:  Chang Hu; Vikram Anjur; Krishnakant Saboo; K Rajender Reddy; Jacqueline O'Leary; Puneeta Tandon; Florence Wong; Guadalupe Garcia-Tsao; Patrick S Kamath; Jennifer C Lai; Scott W Biggins; Michael B Fallon; Paul Thuluvath; Ram M Subramanian; Benedict Maliakkal; Hugo Vargas; Leroy R Thacker; Ravishankar K Iyer; Jasmohan S Bajaj
Journal:  Am J Gastroenterol       Date:  2021-02-01       Impact factor: 10.864

8.  Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease.

Authors:  Z M Younossi; G Guyatt; M Kiwi; N Boparai; D King
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

Review 9.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

Review 10.  Preventing 30-day hospital readmissions: a systematic review and meta-analysis of randomized trials.

Authors:  Aaron L Leppin; Michael R Gionfriddo; Maya Kessler; Juan Pablo Brito; Frances S Mair; Katie Gallacher; Zhen Wang; Patricia J Erwin; Tanya Sylvester; Kasey Boehmer; Henry H Ting; M Hassan Murad; Nathan D Shippee; Victor M Montori
Journal:  JAMA Intern Med       Date:  2014-07       Impact factor: 21.873

View more
  1 in total

1.  Palliative Care, Patient-Reported Measures, and Outcomes in Hospitalized Patients With Cirrhosis.

Authors:  Eric S Orman; Andrew Yousef; Chenjia Xu; Hani Shamseddeen; Amy W Johnson; Lauren Nephew; Marwan Ghabril; Archita P Desai; Kavish R Patidar; Naga Chalasani
Journal:  J Pain Symptom Manage       Date:  2022-02-21       Impact factor: 5.576

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.